Anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (Barbara Ann Karmanos Cancer Institute)

N/A

Report date: 2026/03/19 16:59:41

Base Information

Drug NameAnti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (Barbara Ann Karmanos Cancer Institute)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-CD3CD20-directed cytolytic effectsAnti-CD20

TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD20

Therapy Area/IndicationsLymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute Barbara Ann Karmanos Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBarbara Ann Karmanos Cancer Institute National Cancer Institute

Active IndicationsN/A

Inactive IndicationsLymphoma

Other Information

ATC CodeN/A